1994
DOI: 10.1097/00001813-199409001-00142
|View full text |Cite
|
Sign up to set email alerts
|

Phase I/II trial of dexverapamil (DEX), epirubicin (EPI) plus GM-CSF in advanced pancreatic cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1997
1997
1997
1997

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Haematological toxicity of modulators has been reported in clinical trials (Figueredo et al, 1990;Scheithauer et al, 1993;Bartlett et al, 1994). Pgp modulation on haemopoietic progenitors and also pharmacokinetic changes of the cytotoxic drug due to Pgp modulation on liver or kidney have been suggested.…”
Section: Discussionmentioning
confidence: 99%
“…Haematological toxicity of modulators has been reported in clinical trials (Figueredo et al, 1990;Scheithauer et al, 1993;Bartlett et al, 1994). Pgp modulation on haemopoietic progenitors and also pharmacokinetic changes of the cytotoxic drug due to Pgp modulation on liver or kidney have been suggested.…”
Section: Discussionmentioning
confidence: 99%